Coming Soon

KalVista Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for diseases with high unmet medical need, particularly in the area of diabetic eye disease and other ophthalmic conditions.
Public Funding Received
2015-06-01
Clinical development to PoC of a novel oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME)
Collaborative R&D
2014-02-01
The development of a companion diagnostic to improve patient management and pharmacoeconomics in diabetic retinopathy
GRD Development of Prototype
2012-12-01
Pre-clinical development of novel oral plasma kallikrein inhibitors for the treatment of diabetic macular edema
Collaborative R&D